Inexpensive drug can reduce deaths from heart failure, study finds

Nov 16, 2010

( -- The risk of death and hospitalisation of patients with heart failure can be reduced considerably by administering a cheap and easily available drug, according to new medical research.

A study, led by doctors from France, USA, Australia, Netherlands, Scotland and Sweden, under the Chairmanship of Professor Faiez Zannad (University of Nancy) and Prof Bertram Pitt (University of Michigan), has shown the drug eplerenone can cut cardiovascular deaths and hospitalisations of patients with heart failure by 37 per cent in relative terms (7.6 per cent in absolute terms).

The finding could change the way patients are treated, helping to improve the lives of people with heart failure – a long-term, condition, affecting about two per cent of the population in Scotland.

Heart failure is the result of a weakened heart muscle caused by previous damage from heart attacks, high blood pressure and other causes. The heart pumps less effectively than normal, leading to breathlessness, fatigue, swollen ankles, frequent admission to hospital and shortened life-expectancy. Heart failure is a major cause of disability and death and a huge burden to the NHS as well as patients and their families.

Professor John McMurray, Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, who was part of the small team that designed and led the trial, said: “This was an unusually successful trial: the treatment not only reduced both deaths and hospital admissions from all causes, but was also well-tolerated and is inexpensive. We do not see such positive results very often.

“This trial will change the way we manage our patients. Everyone with heart-failure should be considered for treatment with a drug of this type – it will make patients feel better, stay out of hospital and live longer.”

The study, reported in the New England Journal of Medicine, recruited 2,737 patients from 29 countries, all of whom were being treated for mild forms of systolic heart failure.

Over a period of four years from 30 March 2006 to 25 May 2010, 1,364 were given the drug while 1,373 were given a placebo.

Eplerenone is a mineralocorticoid antagonist which works by blocking the actions of certain hormones, aldosterone and cortisol, which are produced in excessive amounts in patients with heart failure and are harmful.

The results showed that cardiovascular death or hospitalisation for heart failure occurred in 18.3 per cent of the eplerenone group and in 25.9 per cent of the placebo group.

Prof McMurray said: “Eplerenone is not expensive and there is a related, generic, drug, spironolactone, with similar properties, which is likely have similar effects. This type of treatment should be available and affordable across the globe. Our trial has huge public health implications.”

The study, entitled ‘EMPHASIS: Eplerenone in Mild Patients and Survival Study in ’, is published in the latest edition of the New England Journal of Medicine.

Explore further: Prescription drug monitoring programs offer multiple benefits

Related Stories

Heart pumps save lives

Jun 14, 2010

Heart failure is a very common condition: around 200,000 people in Sweden have been diagnosed with the disease. Some patients with life-threatening heart failure can be helped by mechanical heart pumps, reveals a thesis from ...

New heart failure device is tested

Oct 17, 2006

Physicians at 50 U.S. medical facilities are taking part in a multinational clinical trial of a device designed to help heart failure victims.

Recommended for you

FDA clears drug for leading form of cystic fibrosis

15 hours ago

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.